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A B S T R A C T 
The introduction of robot-assisted surgery, and 
specifically the da Vinci Surgical System, is one 
of the biggest breakthroughs in surgery since the 
introduction of anaesthesia, and represents the 
most significant advancement in minimally invasive 
surgery of this decade. One of the first surgical uses 
of the robot was in orthopaedics, neurosurgery, and 
cardiac surgery. However, it was the use in urology, 
and particularly in prostate surgery, that led to its 
widespread popularity. Robotic surgery, is also widely 
used in other surgical specialties including general 
surgery, gynaecology, and head and neck surgery. In 
this article, we reviewed the current applications of 
robot-assisted surgery in different surgical specialties 
with an emphasis on urology. Clinical results as 
compared with traditional open and/or laparoscopic 
surgery and a glimpse into the future development 
of robotics were also discussed. A short introduction 
Current status of robot-assisted surgery
Introduction
The introduction of robot-assisted surgery, and 
specifically the da Vinci Surgical System, is one 
of the biggest breakthroughs in surgery since the 
introduction of anaesthesia, and represents the 
most significant advancement in minimally invasive 
surgery of this decade. One of the first surgical uses 
of the robot was in orthopaedics, neurosurgery, and 
cardiac surgery. However, it was the use in urology, 
and particularly in prostate surgery, that led to its 
widespread popularity.1 Robotic surgery is also 
widely used in other surgical specialties including 
general surgery, gynaecology, and head and neck 
surgery. 
 Urology has long been adoptive to advances 
in technology. It is not surprising that soon after 
robotic technology was first applied to medical 
science, it was well received by the urology 
community. Robotic surgery has applications in 
many aspects of urological surgery. Since 1998, there 
have been over 4000 peer-reviewed publications 
in various specialties on the da Vinci Surgery, of 
which 46% pertain to urology, 17% to cardiothoracic 
surgery, 13% to general surgery, 8% to gynaecology, 
7% to general surgical topics (including outcomes, 
trends, and cost-effectiveness for different types of 
robotic surgery), 4% to paediatric surgery, and 2% to 
otorhinolaryngology.2 
 Literature review of current applications 
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of robotics in different surgical specialties with 
an emphasis on urology was performed. Clinical 
results as compared with traditional open and/or 
laparoscopic surgery and a glimpse into the future 
development of robotics will be discussed. A short 
introduction on emerging areas of robotic surgery 
will also be briefly reviewed. 
History of the surgical robot 
The world’s first surgical robot, ‘Arthrobot’ , was 
born in 1983 and was designed to assist orthopaedic 
procedures. In 1985, PUMA 560 (Unimate, New 
Jersey, US) was used to precisely place a needle for 
computed tomography–guided brain biopsy. This 
was followed in 1988 by ROBODOC (Integrated 
Surgical Systems, Delaware, US), a system used in 
total hip arthroplasty to allow precise preoperative 
planning, and to mill out precise fittings in the femur 
for hip replacement. The first application in urology 
occurred in 1988 at Imperial College (London, UK) 
with the use of the PROBOT in clinical trials to 
perform transurethral surgery. In 1993, Computer 
Motion, Inc (Santa Barbara [CA], US)—the original 
leading medical robots supplier—released AESOP 
(Automated Endoscopic System for Optimal 
Positioning), a robotic arm to assist in laparoscopic 
camera holding and positioning. The CyberKnife 
(Accuray, Sunnyvale [CA], US) was introduced in 
1994 for stereotactic radiosurgery in neurosurgery. 
REVIEW ARTICLECME
of the emerging areas of robotic surgery were also 
briefly reviewed. Despite the increasing popularity 
of robotic surgery, except in robot-assisted radical 
prostatectomy, there is no unequivocal evidence to 
show its superiority over traditional laparoscopic 
surgery in other surgical procedures. Further trials 
are eagerly awaited to ascertain the long-term results 
and potential benefits of robotic surgery. 
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機器人手臂輔助手術的現況
吳翠蓮、談寶雛
機器人手臂輔助手術的引進，尤其是達文西手術系統，是手術引進麻
醉以來最大的突破之一，代表着這十年間微創手術最顯著的進步。骨
科、神經外科和心臟外科手術率先採用機器人輔助。然而，正是泌尿
外科（特別是前列腺手術）導致機器人輔助的廣泛普及。機器人手臂
輔助手術也廣泛應用於其他外科專科，包括外科、婦科和頭頸部手
術。本文回顧機器人輔助手術在不同外科專業目前的應用，特別針對
泌尿外科方面，以及討論機器人輔助手術的臨床效果，並與較傳統的
開放和腹腔鏡手術比較，來窺探機器人技術的未來發展。此外，亦會
簡短回顧機器人手術在泌尿科應用的新興領域。儘管機器人手術日漸
普及，除了機器人輔助根治性前列腺切除術，目前並沒有明確證據顯
示機器人手術在其他外科手術優勝於傳統的腹腔鏡手術。須作進一步
的試驗評估機器人手術的長遠和潛在效益。
The year 1998 was a significant landmark, with 
the introduction of ZEUS Robotic Surgical System 
(Computer Motion, Inc) and the da Vinci Surgical 
System (Intuitive Surgical, Inc, Sunnyvale [CA], US). 
Both systems comprised a surgical control centre 
and robotic arms. The first da Vinci robotic surgical 
procedure was a robot-assisted heart bypass, and 
it took place in Germany in 1998.3 In 2000, the da 
Vinci robot was given approval by the US Food and 
Drug Administration (FDA) for use in laparoscopic 
procedures. The first reported robot-assisted radical 
prostatectomy (RARP) took place in Paris, France, 
in the same year.4 Intuitive Surgical, Inc took over 
Computer Motion, Inc in 2003 and is now the 
sole company marketing robotic surgical devices. 
Other companies such as Olympus and Samsung 
are developing new robotic surgical systems, with a 
promise of lower cost and more compact machines.
The da Vinci Surgical System 
The da Vinci Surgical System comprises three 
components: a surgeon’s console, a patient-side 
robotic cart with four robotic arms manipulated by 
the surgeon (one to control the camera and three 
to manipulate instruments), and a high-definition 
three-dimensional (3D) vision system. Articulating 
surgical instruments are mounted on the robotic 
arms which are introduced into the body through 
cannulas.2 The US FDA approved the system for 
general laparoscopic surgery (gallbladder diseases 
and reflux) in July 2000, for urological procedures 
in 2001, for mitral valve repair surgery in November 
2002, and for gynaecological conditions in 2005.
Advantages and cost-effectiveness 
of the robotic surgery system 
Robotic surgery by the da Vinci Surgical System 
(Intuitive Surgical, Inc) has been popularised by its 
widespread usage in radical prostatectomy (RP). 
The robotic system overcomes the limitations of 
the standard laparoscopic approach and allows for 
precise dissection in a confined space and hence the 
increasing application of robot-assisted laparoscopic 
prostatectomy in expert centres. These advantages 
include stable operator-controlled camera, high-
definition 3D magnified view of 10 to 12 times, 
articulating instruments with seven degrees of 
freedom, motion scaling, and tremor filtration. 
Moreover, carbon dioxide insufflation during the 
procedure helps in reduction of venous ooze, thus 
leading to improved visualisation and reduced 
blood loss.5 Across different specialties, the majority 
of robotic surgeries have been associated with a 
decreased length of stay, and fewer complications 
including a lower transfusion rate and in-hospital 
death rate.6 However, robot-assisted laparoscopic 
surgery is costlier than laparoscopic surgery and 
open surgery. 
 An analysis of new technology and health 
care costs of 20 different robot-assisted surgeries 
published in the New England Journal of Medicine 
in 20107 showed that the use of the robot added 13% 
(US$3200) to the total average cost of a procedure in 
2007. However, there were no large-scale randomised 
trials to definitely show that robot-assisted surgery 
was superior to other procedures.7
 Additional studies are needed to better 
delineate the comparative and cost-effectiveness 
of robot-assisted laparoscopic surgery relative to 
laparoscopic surgery and open surgery. Robotic 
surgery provides similar postoperative outcomes 
to laparoscopic surgery but has a reduced learning 
curve. Although costs are currently high, increased 
competition from manufacturers and wider 
dissemination of the technology may drive costs 
down. Further trials are needed to evaluate long-
term outcomes in order to fully evaluate the value of 
robots in surgical procedures.8
Application in urology 
There has been a continuous expansion of robot-
assisted surgery for both upper and lower urinary 
tract diseases in urology. This is especially true in 
robotic prostatectomy, where the initial reports of 
robotic prostatectomy by Menon et al9 led to an 
exponential growth of robotic surgery in clinically 
localised prostate cancer. More recently, there 
has been an increasing number of robotic renal 
surgeries10 and robotic cystectomy in centres of 
excellence.11
Robotic radical prostatectomy
Prostate cancer is the most common solid organ 
malignancy in men in the US, and the second 
leading cause of cancer death. It is the second most 
#  Robot-assisted surgery  # 
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common cancer in the world, with a world age-
standardised rate of 28 per 100 000 males.12 There is 
a rapidly increasing incidence of prostate cancer in 
Asian countries due to a more westernised lifestyle.13 
In Hong Kong, prostate cancer is the third most 
common cancer, accounting for 10.7% of all male 
malignancies; it is the fifth major cause of cancer 
death, responsible for 4.1% of all cancer deaths in 
Hong Kong.14
 Radical prostatectomy is a standard treatment 
option for localised carcinoma of the prostate, with 
a demonstrated survival advantage when compared 
with watchful waiting in the randomised controlled 
trial SPCG-4 (Scandinavian Prostate Cancer Group 
Study No. 4).15 Radical prostatectomy showed a 
significant relative risk reduction in cancer-specific 
mortality as compared with watchful waiting—44% 
decrease at 10 years, 35% at 12 years, and 38% at 15 
years.15,16 
 However, open RP is associated with high 
morbidity rates. Schuessler et al17 introduced 
laparoscopic RP in 1997 with the aim of reducing 
morbidity. The advantages of laparoscopic 
prostatectomy, as reported in initial expert series, 
showed a lower mean blood loss and transfusion rate, 
decreased mean hospital stay, and earlier removal of 
the Foley catheter compared with results from open 
prostatectomy series.18
 However, the technical demands of 
laparoscopic RP prevented its widespread use by 
the average urologist, with a limited case load. The 
introduction of the da Vinci Surgical System was a 
breakthrough in minimally invasive prostatectomy. 
Menon et al1 from the Vattikuti Urology Institute in 
Detroit [MI], US are responsible for the development 
and popularisation of RARP. This technique offers all 
the advantages of minimally invasive laparoscopic 
prostatectomy with the added advantage of shorter 
learning curve and improved ergonomics, leading 
to the widespread use and acceptance of RARP 
worldwide. 
 Ahlering et al19 studied the learning curve for 
robotic prostatectomies, and found that the robotic 
system might significantly shorten the learning 
curve for an experienced open yet laparoscopy-naїve 
surgeon. The learning curve for achieving 4-hour 
proficiency has been shown to be 12 patients.19
 Robot-assisted RP has overtaken open RP as 
the most common surgical approach for RP ever 
since the FDA approval in 2001, and is estimated to 
account for approximately 80% of all RP procedures 
in the US.20 
 However, the rise in robotic procedures was 
initially not backed by any evidence on clinical 
benefits. No randomised trial showed the benefits 
of robotic surgery until the publication of the 
nationwide series by Trinh et al.21 Data from this 
series demonstrated superior adjusted perioperative 
outcomes after RARP in virtually all examined 
outcomes. Of 19 462 RPs, 61.1% were RARPs, 38.0% 
were open RPs, and 0.9% were laparoscopic RPs. In 
multivariable analyses, patients undergoing RARP 
were less likely to receive a blood transfusion (odds 
ratio [OR]=0.34; 95% confidence interval [CI], 0.28-
0.40), to experience an intra-operative complication 
(OR=0.47; 95% CI, 0.31-0.71) or a postoperative 
complication (OR=0.86; 95% CI, 0.77-0.96), and to 
experience a prolonged length of stay (OR=0.28; 95% 
CI, 0.26-0.30) [Table 121].
 A recent territory-wide review in Hong Kong22 
showed that a total of 235 patients underwent 
RARP between 2005 and 2009, with a 37.3% rate 
TABLE 1.  Intra-operative and postoperative outcomes for open and robotic radical prostatectomy surgery21
Abbreviations: CI = confidence interval; OR = odds ratio
Outcome No. (%) OR (95% CI) P value
Open (n=7389) Robotic (n=7598) Robotic vs open
Homologous blood transfusion 572 (7.7) 184 (2.4) 0.30 (0.25-0.35) <0.001
Intra-operative complication 73 (1.0) 33 (0.4) 0.44 (0.29-0.66) <0.001
Postoperative complication 
Overall 823 (11.1) 705 (9.3) 0.82 (0.73-0.91) <0.001
Cardiac 96 (1.3) 68 (0.9) 0.69 (0.50-0.94) 0.018
Respiratory 191 (2.6) 105 (1.4) 0.53 (0.42-0.67) <0.001
Vascular 45 (0.6) 30 (0.4) 0.65 (0.41-1.03) 0.065
Operative wound 48 (0.6) 35 (0.5) 0.71 (0.46-1.10) 0.121
Genitourinary 86 (1.2) 90 (1.2) 1.02 (0.76-1.37) 0.907
Miscellaneous medical 459 (6.2) 432 (5.7) 0.91 (0.79-1.04) 0.173
Miscellaneous surgical 121 (1.6) 122 (1.6) 0.98 (0.76-1.26) 0.877
Length of stay >2 days 2923 (39.6) 1105 (14.5) 0.26 (0.24-0.28) <0.001
In-hospital mortality 6 (0.1) 1 (0.01) 0.16 (0.02-1.35) 0.092
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of trifecta (cancer cure, continence, and return of 
sexual function) at 12 months, demonstrating the 
feasibility, safety, and efficacy of RARP in low-to-
intermediate volume centres. In a series from a 
high-volume centre, trifecta rates at 6 weeks, 3, 6, 12 
and 18 months after RARP were 43%, 65%, 80%, 86% 
and 91%, respectively.23 
 However, the majority of urologists in Hong 
Kong are not from high-volume centres, thereby, 
not being able to achieve these benchmark and 
commendable results. Thus, it is now debated 
whether robotic prostatectomy should be limited 
to high-volume centres of excellence. A randomised 
trial of open versus robot-assisted RP was 
commenced in October 2010 in Australia.24 Overall, 
200 men per treatment arm (400 men in total) are 
being recruited after diagnosis and before treatment 
through a major public hospital out-patient clinic 
and randomised to  robotic prostatectomy or open 
prostatectomy. Clinical outcomes, quality-of-life 
outcomes, and cost-effectiveness are being critically 
and prospectively analysed to compare outcomes.24 
To date, more than 250 patients have been recruited. 
Results are eagerly awaited.25 
Robotic partial nephrectomy
In the recent decade, there has been a stage and 
size migration of renal tumours. Less than 10% of 
new cases present with the classic triad of gross 
haematuria, loin pain, and mass. The incidence of 
small renal mass has increased by 3.7% per year 
with widely available abdominal imaging such as 
ultrasonography over the past decade.26 Numerous 
studies have shown that renal insufficiency is 
associated with increased cardiovascular events, 
hospitalisation, and mortality,27 leading to increasing 
role of renal-preserving strategies in the treatment 
of localised renal cell carcinoma. Data from more 
than 2000 patients who underwent surgery at 
Memorial Sloan Kettering Cancer Center from 1989 
to 2005 showed that radical nephrectomy was an 
independent factor for new-onset chronic kidney 
disease.28 According to the European Association 
of Urology guidelines on renal tumour, nephron-
sparing surgery is the standard procedure for 
solitary renal tumours measuring up to 7 cm in 
diameter.29 Benefits of nephron-sparing surgery over 
radical nephrectomy include equivalent oncological 
outcome in tumours measuring less than 4 cm, 
and probably up to 7 cm in diameter, avoidance of 
overtreatment of benign lesions which account for 
up to 20% of small renal masses, further treatment 
options available if contralateral kidney recurrence 
occurs, better quality of life, and decreased overall 
mortality.30 Moreover, both procedures have 
comparable survival rates.30
 Open partial nephrectomy (OPN) currently 
remains the standard procedure for partial 
nephrectomy. However, OPN is associated with 
significant morbidity: the muscle-cutting flank 
incision may involve removal of a lower rib, leading 
to flank bulge, pain, paraesthesia, and hernia 
formation. The introduction of laparoscopic partial 
nephrectomy was aimed at reducing the morbidity 
associated with OPN. 
 Laparoscopic partial nephrectomy offers 
the advantages of shorter length of stay, decreased 
operative blood loss, and a shorter operating time 
versus OPN. However, it is associated with longer 
warm ischaemic time, more postoperative urological 
complications, and increased number of subsequent 
procedures. State-of-the-art surgical expertise and 
technique are prerequisites for laparoscopic partial 
nephrectomy.31 Thus, the procedure is not routinely 
performed in many centres in view of its prolonged 
learning curve. 
 Robot-assisted partial nephrectomy shows 
promise in bridging the gap between open and 
laparoscopic approaches, providing similar 
oncological results to radical nephrectomy and 
improved morbidity with a shorter learning curve 
than laparoscopic partial nephrectomy. Robot-
assisted partial nephrectomy has been shown to be 
a safe and viable alternative to laparoscopic partial 
nephrectomy in some published case series,32,33 
providing equivalent early oncological outcomes to 
laparoscopic partial nephrectomy, and the additional 
advantages of decreased hospital stay, less intra-
operative blood loss, and shorter warm ischaemic 
time averaging less than 20 minutes. Moreover, 
operative parameters for robot-assisted partial 
nephrectomy are less affected by tumour complexity 
and surgical expertise of the surgeon as compared 
with laparoscopic partial nephrectomy. A case series 
published by our centre34 showed that robot-assisted 
laparoscopic partial nephrectomy was technically 
feasible, with the advantage of statistically significant 
decreased warm ischaemic time (31 vs 40 minutes; 
P=0.032; Table 26).
Robotic cystectomy
Radical cystectomy and pelvic lymph node 
dissection are the standard treatment options for 
muscle-invasive carcinoma of the bladder. However, 
this procedure is associated with high morbidity of 
up to 50% and mortality of up to 5%, even in centres 
of excellence.35 Data from the Surgical Outcomes 
Monitoring & Improvement Program Report of the 
Hong Kong Hospital Authority showed that radical 
cystectomy is a surgical procedure associated with 
the highest morbidity and mortality among all 
surgical operations in Hong Kong.36 From 2009 to 
2010, the 30-day crude mortality rate was 9.7%, and 
the 30-day crude morbidity rate was 65.3%.36 
 Laparoscopic cystectomy was introduced 
with the aim of decreasing associated morbidity 
#  Robot-assisted surgery  # 
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and length of hospital stay. The first laparoscopic 
radical cystectomy was performed in 1992.37 Case 
series performed at expert centres showed that 
when compared with open surgery, laparoscopic 
cystectomy resulted in a lower morbidity rate with 
significantly lower intra-operative blood loss and 
transfusion rates, lower pain scores, and allowing a 
more rapid resumption of oral intake and a shorter 
hospital stay.38 However, laparoscopic radical 
cystectomy is technically challenging, with a steep 
learning curve. 
 Robot-assisted radical cystectomy (RARC) was 
introduced as an attempt to offset the high technical 
skill required for laparoscopic cystectomy, and was 
the first procedure performed in 2003 by Beecken et 
al.39 A recent retrospective analysis40 on consecutive 
series of patients undergoing radical cystectomy 
(100 RARCs and 100 open radical cystectomies) 
with curative intent over a 4-year period suggests 
that patients undergoing RARC have perioperative 
oncological outcomes comparable with open 
radical cystectomies, and lower overall and major 
complication (Clavien score ≥3) rates (35% vs 57%; 
P=0.001 and 10% vs 22%; P=0.019, respectively), less 
blood loss, and shorter hospital stay versus open 
radical cystectomies. There were no significant 
differences between the two groups for pathological 
outcomes, including stage, number of nodes 
harvested, or positive margin rates.40
 Although the results for RARC are encouraging, 
long-term functional and oncological control rates 
are still unknown. Randomised, multi-institutional 
comparisons of these techniques will be required 
before widespread adoption of the procedure.
Other robotic applications in urological 
surgery
Reconstructive procedures including pyeloplasty, 
ureteric reimplantation, appendicovesicostomy, and 
augmentation enterocystoplasty are increasingly 
performed with the assistance of the robot.41 Data 
on pyeloplasty showed that the robotic approach 
is associated with a lower transfusion rate and a 
shorter length of stay as compared with the open and 
laparoscopic approaches (Table 36).
 Robot-assisted microsurgery is being util-
ised to a greater degree in andrology including pro- 
cedures such as vasectomy reversal, subinguinal 
varicocelectomy, targeted spermatic cord denervation 
(for chronic orchialgia), and microsurgical testicular 
sperm extraction.42
Application in gynaecology
The da Vinci Surgical System was approved for 
use in gynaecological surgery in the US in 2005. 
Applications of robotics in gynaecology include 
hysterectomy, myomectomy, oophorectomy, 
ovarian cystectomy, resection of endometriosis and 
lymphadenectomy, with an increasing role of robotic 
surgery in gynaecological oncology. 
 Endometrial carcinoma is the most common 
malignancy of the female reproductive organs and 
the consensus in the literature is that robotic surgery 
is preferable to open surgery and is equivalent to 
laparoscopy in many aspects.43 The robotic platform 
offers distinct advantages in certain populations, 
such as the morbidly obese, and is becoming a 
commonly used procedure.43
TABLE 2.  Comparing outcomes of partial nephrectomy (robotic vs laparoscopic vs open)6
Outcome No. (%) P value
RALS (robotic) LS (laparoscopic) OS (open)
Complications
Cardiac DS 11 (5.3) 68 (3.9) 0.608
Respiratory DS 15 (7.3) 141 (8.0) 0.115
Genitourinary 0 DS 82 (4.6) <0.001
Wound 0 0 34 (2.0) <0.001
Vascular DS DS DS 0.015
Miscellaneous medical 28 (11.2) 35 (16.8) 262 (14.8) 0.717
Miscellaneous surgical 18 (7.3) 11 (5.1) 89 (5.1) 0.813
Death 0 0 0 Not applicable
Any complication 46 (18.3) 55 (26.7) 512 (28.9) 0.26
Blood transfusion 20 (8.1) 13 (6.1) 137 (7.8) 0.922
LOS (days)* 2.8 ± 2.3 3.6 ± 3.3 4.5 ± 6.8 <0.001
Routine discharge 248 (97.9) 205 (99.2) 1608 (90.9) 0.006
Abbreviations: DS = data suppressed per Nationwide Inpatient Sample for 0<n<11; LOS = length of stay; LS = laparoscopic surgery; 
OS = open surgery; RALS = robot-assisted laparoscopic surgery
* Data are shown as mean ± standard deviation
  #  Ng and Tam #
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 Similarly, in cervical carcinoma, the published 
data comparing robotic radical hysterectomy to 
traditional laparoscopy or laparotomy showed that 
the robotic approach produces more favourable 
perioperative outcomes, including a lower blood loss, 
shorter length of stay, and equivalent or lower rates 
of intra-operative and postoperative complications.44 
 Hysterectomy for benign conditions is one 
of the most commonly performed procedures 
in women, with a one in nine chance of a woman 
undergoing the procedure in her lifetime.45 Between 
2007 and 2010, the utilisation of robot-assisted 
hysterectomy for benign gynaecological disorders 
increased substantially. However, robot-assisted and 
laparoscopic hysterectomy had similar morbidity 
profiles, offered little short-term benefit, but resulted 
in substantially more costs.46 A 2012 Cochrane review 
of robotic surgery for benign gynaecological diseases 
showed that robotic surgery was not associated with 
improved effectiveness or safety, but increased the 
cost of the procedure substantially.47
 The existing limited evidence shows that 
robotic surgery does not benefit women with 
gynaecological diseases in terms of effectiveness or 
safety. Further well-designed randomised controlled 
trials with complete reported data are required to 
confirm or refute this conclusion.
Application in colorectal surgery
Laparoscopic colorectal surgery has become the 
preferred standard of care in colorectal surgery and 
has been proven to be as safe and effective as open 
surgery, and associated with a lower blood loss and 
shorter length of stay. Robotic technology aims to 
overcome some of the limitations of conventional 
laparoscopic surgery. However, the role of robotics in 
colorectal surgery remains controversial. Delaney et 
al48 compared robotic versus traditional laparoscopic 
colorectal surgery, and reported that robotic 
colectomy was a feasible and safe procedure, but 
involved greater costs and longer operating times. 
 In a comparative study between robotic versus 
laparoscopic right hemicolectomy, deSouza et al49 
reported that the robotic approach was safe and 
feasible, but associated with longer operating times 
and higher costs as compared with pure laparoscopic 
approach. However, there were similar rates of 
overall morbidity, lymph node dissection, blood loss, 
conversion rate, and length of hospital stay in both 
groups, showing no benefit of robotic approach for 
right hemicolectomy over laparoscopic surgery.
 The emerging role of robotic surgery in 
colorectal conditions is in rectal pathologies, 
especially in patients with a narrow pelvis. Total 
mesorectum excision (TME) has been established 
as a standard surgical technique in rectal cancer 
surgery.50 Laparoscopic TME in a narrow pelvis 
and locally advanced disease is a technically 
demanding procedure, and it is associated with a 
high conversion rate, high positive surgical margin, 
and poor continence and erectile function.51,52
 Robotic nerve-sparing TME was shown in 
a randomised study to have significantly shorter 
length of stay (6.9 days vs 8.7 days, P<0.001) with 
similar mean operating time, conversion rate, and 
specimen quality as compared with its counterpart 
laparoscopic procedure.53 In another series by Kim 
et al,54 robotic TME showed a shorter recovery time 
TABLE 3.  Comparing outcomes of pyeloplasty (robotic vs laparoscopic vs open)6
Outcome No. (%) P value
RALS (robotic) LS (laparoscopic) OS (open)
Complications
Cardiac DS 0 DS 0.573
Respiratory DS 0 DS 0.193
Genitourinary DS DS 16 (3.7) 0.242
Wound 0 0 0 Not applicable
Vascular 0 0 DS 0.496
Miscellaneous medical DS DS 16 (3.9) 0.913
Miscellaneous surgical DS 0 DS 0.049
Death 0 0 0 Not applicable
Any complication DS DS 38 (9.1) 0.505
Blood transfusion DS 0 DS <0.001
LOS (days)* 2.2 ± 1.8 2.2 ± 1.2 3.0 ± 3.0 0.002
Routine discharge 166 (97.4) 29 (100.0) 407 (97.5) 0.371
Abbreviations: DS = data suppressed per Nationwide Inpatient Sample for 0<n<11; LOS = length of stay; LS = laparoscopic surgery; 
OS = open surgery; RALS = robot-assisted laparoscopic surgery
* Data are shown as mean ± standard deviation
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for erectile function as compared with laparoscopic 
TME (6 vs 12 months). The authors postulated 
that the precise identification of anatomical planes 
and smaller neural components was facilitated by 
magnified view and superior movement of wristed 
robotic instruments.54 
 Recent studies48-55 have confirmed robotic 
colorectal surgery to be feasible and oncologically 
safe with potentially significant benefits in rectal 
surgery. However, we await long-term results 
concerning oncological outcome.
Application in general surgery
The application of robotics in general surgery has 
been evolving, and the number of procedures has 
been growing over the past decade, especially in 
bariatric surgery, fundoplication, and hepatobiliary 
surgery, although robotic approach is not routinely 
employed for those procedures. 
 Bariatric procedures can be complex and 
challenging in view of large patients, large livers, 
thick abdominal walls and substantial visceral fat, 
making exposure, dissection and reconstruction 
difficult. The first robotic bariatric procedure was 
an adjustable gastric banding procedure performed 
by Belgian surgeons in September 1998.56 Since 
then, the robotic approach has become an option 
to standard laparoscopy. Robotic procedures in 
bariatric surgery include robotic adjustable gastric 
banding, robotic sleeve gastrectomy, robotic gastric 
bypass, and biliopancreatic diversion with duodenal 
switch.57 Robotic bariatric procedures appear to have 
a decreased rate of gastro-intestinal leaks, lower risk 
of needing follow-up surgery, and a lower conversion 
rate to open surgery.58
 Robotic Heller myotomy for achalasia has 
been shown to result in fewer oesophageal tears, and 
improved quality of life after surgery in studies as 
compared with traditional laparoscopic surgery.59
 Local data on the feasibility and safety of 
robotic surgery for hepatocellular carcinoma 
showed favourable short-term outcomes, including 
hospital mortality and morbidity rates of 0% and 
7.1%, respectively; the mean hospital stay was 6.2 
days. The 2-year overall and disease-free survival 
rates were 94% and 74%, respectively. However, the 
long-term oncological results remain uncertain.60
Application in endocrine surgery
Thyroid surgery is traditionally performed via a 
collar incision. However, with a large portion of 
patients being young females, there is a demand for 
avoiding the transverse cervical incision. This led to 
the introduction of endoscopic techniques, with the 
advantages of better cosmetic outcome and reduced 
paraesthesia of the anterior neck.61 However, these 
endoscopic techniques are technically demanding 
and time-consuming.
 The introduction of the da Vinci Surgical 
System has further revolutionised the surgical 
management of thyroid diseases. Robotic surgery 
overrides the drawbacks of endoscopic surgery, 
being associated with better visualisation and 
improved fine manipulation within the deep 
and narrow cervical space. Better visualisation is 
achieved through 10 to 12 times of magnification and 
3D images, facilitating enhanced precise anatomical 
dissection. Robotic thyroidectomy is also associated 
with a shorter learning curve than endoscopic 
thyroidectomy and causes less musculoskeletal 
strain to the surgeon.62
 The use of robots in thyroid surgery is rapidly 
increasing. Results are promising in case series, 
with more than 6000 procedures being performed 
in Korea between 2007 and 2011.63 However, 
randomised controlled trials comparing robotic with 
conventional open or endoscopic surgery are needed 
to assess the long-term oncological outcomes and 
functional outcomes.63
Application in head and neck 
surgery 
The use of robotics in the field of head and neck 
surgery was adopted recently, with the first case 
series published in 2006.64 Robotic surgery allows 
transformation of open surgical management of 
head and neck cancer to a transoral minimally 
invasive approach. Robotic approach in head and 
neck surgery has provided surgeons with the ability 
to access anatomical locations that were previously 
managed only via open techniques. This has resulted 
in decreased overall morbidity and excellent 
functional results with equivalent oncological 
outcomes. Transoral robotic surgery provides access 
to the oropharynx, hypopharynx, larynx, oral cavity, 
parapharyngeal space, and skull base via the oral 
aperture. It is useful in resection of the tumour and 
in free-flap reconstruction.
 The advantages of robotic surgery in patients 
with head and neck cancer are access to anatomical 
sites not accessible to conventional endoscopy, 
absence of a neck incision, absence or decreased 
duration of tracheotomy, absence or decreased 
duration of nasogastric or gastric feeding tube, and 
decreased length of hospital stay.65
 Studies have shown that transoral robotic 
surgery is a feasible option for surgical management 
of head and neck tumours, which is associated with 
reduced morbidity.65,66 However, long-term data are 
required for oncological outcomes.
Application in cardiothoracic 
surgery 
The first robotic cardiac procedure was performed 
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in the US in 1999,67 and was one of the earliest 
applications of robotic surgery. Robotic cardiac 
surgical procedures have been performed to repair 
and replace the mitral valve, bypass coronary arteries, 
close atrial septal defects, implant left ventricular 
pacing leads, and resect intracardiac tumours.
  A US study compared robotic sternotomy and 
thoracotomy approaches to mitral valve surgery 
outcomes in more than 700 patients with mitral 
valve disease over a 3-year period. The median 
cardiopulmonary bypass time was 42 minutes 
longer for robotic than complete sternotomy, 39 
minutes longer than for partial sternotomy, and 11 
minutes longer than for right mini-anterolateral 
thoracotomy (P<0.0001). Moreover, the robotic 
procedure was associated with a longer median 
myocardial ischaemic time compared with 
conventional procedures (P<0.0001). The quality 
of mitral valve repair was similar among matched 
groups. Neurological, pulmonary, and renal 
complications were similar among groups. However, 
the robotic approach was associated with the lowest 
occurrences of atrial fibrillation and pleural effusion 
and the shortest hospital stay (median 4.2 days); the 
hospital stays with robotic surgery were 1.0, 1.6, 
and 0.9 days shorter than for complete sternotomy, 
partial sternotomy, and right mini-anterolateral 
thoracotomy, respectively (P<0.001 for all 
comparisons). This series showed that robotic repair 
of posterior mitral valve leaflet prolapse is as safe 
and effective as conventional approaches. Technical 
complexity and longer operating times for robotic 
repair are compensated for by lesser invasiveness 
and shorter hospital stay.68
  Robotic thoracic procedures include resection 
of primary lung cancer, oesophageal tumours, thymic 
diseases, and mediastinal tumours.69 Another US 
series with 168 patients which compared patients 
who underwent robotic pulmonary resection with 
propensity-matched controls undergoing lobectomy 
by rib- and nerve-sparing thoracotomy showed 
that the robotic group had reduced morbidity 
(27% vs 38%; P=0.05), lower mortality (0% vs 3.1%; 
P=0.11), improved mental quality of life (53 vs 40; 
P<0.001), and shorter hospital stay (2.0 vs 4.0 days; 
P=0.02). Moreover, with the additional technical 
modification of completely portal robotic lobectomy 
with four arms, both the median operating time 
(3.7 vs 1.9 hours; P<0.001) and conversion rates to 
traditional thoracotomy (12/62 vs 1/106; P<0.001) 
were lowered.69
  Despite being one of the first specialties to 
utilise the robotic technology, it is still unclear 
whether the technical advantages bring about direct 
merits for patients. Results have been mixed, with 
no unequivocal evidence on benefits of the robotic 
approach. Further evidence is awaited on the use of 
robotics in the cardiothoracic field. 
Future applications for robotics 
Laparoendoscopic single-site surgery (LESS) and 
natural orifice transluminal endoscopic surgery are 
novel techniques that have the potential to further 
minimise the invasiveness and morbidity of surgery. 
However, the technical difficulty of the procedure is 
increased with the need for specialised instruments. 
Robotic technology is rapidly evolving, and with 
the development of new robotic prototypes for 
single-port surgery, it is expected that robotic-
LESS will move forward with the goal of minimising 
complications and improving outcomes.70
Conclusion
Robotic surgery with the da Vinci Surgical System 
is increasingly being applied in a wide range of 
surgical specialties, especially in urology. It aims to 
improve outcomes as compared with open surgery, 
and to overcome the limitations of laparoscopic/
thoracoscopic techniques. Despite the increasing 
popularity of robotic surgery, except in RARP, there 
is no unequivocal evidence to show the superiority of 
robotic surgery over traditional laparoscopic surgery 
in other surgical procedures. Cost-effectiveness 
is also an issue due to the high installation and 
maintenance costs. We eagerly await the introduction 
of different robotic systems by competitors. Further 
randomised studies are required to ascertain the 
long-term results and potential benefits of robotic 
surgery. We eagerly await the results of the ongoing 
randomised trial of open versus robotic RP from 
Australia. 
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